Editorial Features

While Endpoints is known for its daily news reporting on the most consequential items of the day, we also produce a steady stream of long-form items for subscribers that are essential to our editorial mission.
​ Below is a calendar of our planned editorial features. We do offer custom sponsorship options, which include:

ADVERTISING ROADBLOCK

Be the only brand advertiser on the web and in email reports where this content is featured

FEATURED SPONSORED POST

Receive a sponsored post to include in Endpoints News during your editorial feature sponsorship, or to bank and use at a later date.

Editorial Calendar

subject to change

  • feature

    month

    description

  • New Drug Approvals

    January

    An in-depth list of every new drug approval from the previous year, recognition of the companies that brought them to market, and an analysis of their impact on the market at large.

  • JPM

    January

    #JPM21 conference coverage

  • Top 10 AAV & Gene Therapy M&A

    January

    Top M&A in Gene Therapy and AAV

  • Beyond AAV 1.0

    January

    The gene therapy boom was built on AAV delivery tech. And recent clinical work has highlighted a variety of major hurdles; payload limitations, safety threats on high doses, fears associated with waning durability for drugs that intended to be priced once-and-done. What are the leaders in the field doing to break down these barriers — and what could the future hold for AAV and beyond?

  • Top VCs

    February

    Top venture capital firms investing in the biotech sector

  • Setbacks & Snafus

    February

    A list of 10 high-profile mistakes in the industry, examined and analyzed

  • Top Blockbusters

    February

    A list of drugs in development with the biggest launch potential

  • Coming up with a killer preclinical program

    February

    We all know the stats on preclinical programs. Precious few will survive the rigors of clinical trials. Endpoints talks with some of the star investigators doing the translational work behind some of the industry’s most ambitious pipeline efforts. What have they learned about setting up a solid preclinical strategy that gives them better odds of success in humans.

  • Endpoints 100

    March

    Exclusive insights from 100 hand-picked biotech CEOs and A-list investors

  • Top R&D Budgets

    March

    Analysis of the top 15 R&D players in biopharma, and what it means downstream

  • 20 Under 40

    April

    Profiles of young standouts in the biopharma field - the key factors in their success, and their goals as the next generation of industry leaders.

  • ACC

    May

    #ACC21 conference coverage

  • 60 Over 60

    May

    Profiles of sixty of the industries top standouts over 60

  • Reengineering for solid tumors

    May

    CAR-Ts revolutionized the way blood cancers can be treated, but still haven’t really caught on in the market as physicians and patients consider vein-to-vein times, cost and manufacturing snafus. Now a large group of scientists are leading a well-funded drive to adapt this technology for solid tumors, while making the whole process much more economical for patients and payers. The winners will help revolutionize the field. And the race to be first has inspired a furious sprint to the finish line.

  • DIA

    June

    #DIA21 conference coverage

  • ASCO

    June

    #ASCO21 conference coverage

  • BIO

    June

    #BIO21 conference coverage

  • The big platform plays that have been in vogue. But for how long?

    June

    Moderna offers the kind of big upside even the largest institutional investors dream of. And now, you can already hear execs discussing who the next Moderna will be, and whether they can catch that wave themselves. We’ll analyze the numbers on venture capital and IPOs, looking at how platforms are performing compared to smaller groups of drug assets. And how will that influence financing trends for years to come?

  • Top Setbacks & Snafus

    July

    The top setbacks and sanfus for H1 2021

  • The neurosciences comeback: After a lengthy chill, Big Pharma is warming back up to neuro.

    July

    Neurosciences became the stepchild of the pharma industry after a series of ugly setbacks in the clinic drove away the major players. But now, considering the advances in genetics and some new work on old ideas, some of the biggest outfits are driving a comeback of sorts as they team up or buy out some of the upstarts in this space. Endpoints examines the trend, and where it appears we’re headed now.

  • 20 Most Influential Executives

    August

    Profiles of twenty of the industry's most influential executives

  • After the pandemic, antibody R&D remains key

    August

    The onslaught of a global pandemic triggered a frenzy of R&D activity in the industry. But where we saw a revolution in vaccine development in record time, finding new drugs to effectively fight the virus remained difficult and fraught with failure and half-measures of success. Nevertheless, a group of players is still actively engaged in developing a new generation of antibodies to fight this virus, and others to come. We’ll talk to the key leaders in the field about where this is headed, and how it may more broadly affect everyone doing antibody work.

  • ESC

    August

    #ESC21 conference coverage

  • CPhI

    September

    #CPHI21 conference coverage

  • Endpoints 11

    September

    In-depth profiles of the top 11 biotech startups, as selected by Endpoints, and an analysis of the trends that support their promise

  • ESMO

    September

    #ESMO21 conference coverage

  • After a decade of consolidation, who rules the CRO roost?

    September

    Over the past decade, we’ve seen a group of well-financed CROs backed by private equity consolidate and then set out to build new hubs around the world. More recently, we’ve also seen new CROs join the game in China; and both the opportunities in a booming drug development industry and the competition have never been more pronounced. Nicole DeFeudis finds out who the top 10 players and what the key trends are here.

  • A new class of startups is scouting for deals - on both sides of the Pacific

    October

    It used to be that executing a global strategy meant finding a partner for the European market. Now, China has completely changed the way the world works. Startups have been in-licensing for years in a growing set of diseases. And now they are outlicensing to the US and Europe. What happens as more sophisticated R&D organizations go after novel drug targets? Lets find out.

  • Top R&D Budgets & Players

    November

    The top spenders in the global R&D business

  • AHA

    November

    #AHA21 conference coverage

  • The FDA in a post-Covid world

    November

    Covid-19 changed the R&D world. And it’s not going back to what it was before the pandemic. That’s particularly true at the FDA, which worked with developers to make it possible to continue trials when sites were shuttered around the world. We’ll explore what’s likely to stick now that the pandemic is winding down.

  • Women in Biopharma

    December

    Special report that recognizes and celebrates the growing number of enterprising women in biopharma

  • Top Endpoints Stories of the Year

    December

    A review of Endpoints top stories of 2021

  • R&D 15

    December

    Top 15 R&D accomplishments of 2021

  • ASH

    December

    #ASH21 conference coverage

show coverage

The Endpoints editorial team will cover all of the following major medical and business conferences this year.

​Qualified sponsors can increase brand visibility at these events with an exclusive sponsorship of our coverage. These packages will entail:

  • Buyout of all advertising on news articles relating to the event
  • Acknowledgement of the sponsorship in each news article around the event
  • Sponsorship of special email blast containing conference coverage articles
EVENT WHEN
JP MORGAN January
ACC May
ASCO June
BIO June
DIA June
ESC August
CPhI September
ESMO September
AHA November
ASH December

Advertising Specification

  • type

    desktop

    mobile

    tablet

    max size

  • BILLBOARD

    1200x200px

    340x150px

    720x150px

    950k

  • IN-STREAM

    890x250px

    340x150px

    520x200px

    950k

  • IN-ARTICLE

    760x200px

    340x150px

    440x200px

    950k

* Please consider alternative sizes for high-density displays (original dimensions at double size) when submitting your image creatives.